SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 13, 2016, by SIGA Technologies, Inc. The filing discloses the entry into material definitive agreements regarding executive leadership changes. Specifically, the Company appointed a new Chief Executive Officer (CEO) and transitioned the former CEO to the role of Executive Chairman of the Board.
Key Financial Metrics and Compensation
This filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. The financial data provided relates exclusively to executive compensation packages:
- Phillip Louis Gomez, III (New CEO):
- Annual Base Salary: $750,000 (with automatic 3% annual increases starting Jan 1, 2018).
- One-time Long-Term Equity Award: Value of $2,100,000 (restricted stock, RSUs, options, or cash).
- Guaranteed Bonus: $750,000 payable if employed through the one-year anniversary.
- Target Annual Bonus (2017): $750,000 (prorated); 100% of base salary for 2018 and subsequent years.
- Eric A. Rose (Executive Chairman):
- Annual Base Salary: $740,000 for the first year; $700,000 for the second year.
- One-time Equity Award: 300,000 shares of restricted stock or RSUs.
- Bonus Eligibility: Eligible for the 2016 annual bonus program only.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's executive leadership:
- Departure of CEO: Eric A. Rose resigned as Chief Executive Officer effective October 13, 2016.
- Appointment of CEO: Phillip Louis Gomez, III was appointed Chief Executive Officer effective October 13, 2016.
- Role Transition: Eric A. Rose assumed the role of Executive Chairman of the Board under a new two-year agreement.
Guidance, Outlook, Risks, and Contingencies
The filing contains no forward-looking financial guidance or operational outlook. However, it highlights specific contingencies and risks related to executive compensation and ongoing legal matters:
- Severance Provisions: Both executives have significant severance protections. Termination without cause or for good reason triggers one year of continued salary payment and immediate vesting of stock options for Dr. Gomez. Dr. Rose is entitled to continued salary until the scheduled termination date under similar conditions.
- PharmAthene Litigation Constraint: Compensation terms for both executives are explicitly conditioned on the "Plan of Reorganization" and the resolution of litigation with PharmAthene, Inc. Specifically, equity grants awarded after the judgment in the PharmAthene litigation is satisfied (which involves the potential delivery of 100% of the Company's equity to PharmAthene) are excluded from certain vesting and severance provisions.
- Salary Increase Restrictions: Dr. Gomez's discretionary salary increases are restricted until the Company's covenants under the Plan of Reorganization terminate, unless PharmAthene provides prior written consent.
Key Facts for Investor Verification
- Verify the current status of the PharmAthene litigation and the "Plan of Reorganization," as these directly impact executive equity vesting and salary flexibility.
- Confirm the total cash outflow required for the guaranteed bonus ($750,000) for the new CEO and the equity grant valuations.
- Review the severance liabilities associated with the new CEO agreement, particularly the one-year salary continuation and immediate vesting clauses in the event of termination without cause.
- Assess the impact of the leadership transition on the Company's strategic direction, given the new CEO's background in pharmaceutical consulting and vaccine production.